Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region
Issued Date
2024-12-31
Resource Type
eISSN
2164554X
Scopus ID
2-s2.0-85197107773
Pubmed ID
38925146
Journal Title
Human vaccines & immunotherapeutics
Volume
20
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Human vaccines & immunotherapeutics Vol.20 No.1 (2024) , 2362449
Suggested Citation
Phongsamart W., Lou P.J., Sukarom I., Wu Y.H., Zaidi O., Du F., Simon A., Bernauer M. Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region. Human vaccines & immunotherapeutics Vol.20 No.1 (2024) , 2362449. doi:10.1080/21645515.2024.2362449 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99515
Title
Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region
Corresponding Author(s)
Other Contributor(s)
Abstract
There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Program descriptions, recommendations, f unding, and coverage data were extracted. Twenty-five citations were included. As of 2022, eight of the 10 areas of interest include HPV in their national immunization program (NIP) for school-aged girls; full implementation in Indonesia is expected in 2023 whereas Vietnam's NIP does not include HPV. Singapore also includes HPV vaccination for women (18-26 years). None of the HPV vaccination programs include males. In most areas (n = 7), programs include only one vaccine option. While female HPV NIPs are present in the Asia-Pacific region, opportunities remain to strengthen NIPs in broader populations (e.g., males, catch-up cohorts) to expand public health impact and provide gender equity in HPV vaccination.